Safety, tolerability and pharmacokinetics (PK) of the novel HDAC inhibitor CS014: A first-in-human (FIH) trial

Authors
Category Primary study
ConferencePharmacology 2025
Year 2026
This article has no abstract
Epistemonikos ID: c4a60983bddbcd6d76b4bf20db40075110ea4e4a
First added on: Mar 07, 2026